Interim Three Month Data From Ongoing Six Month XOMA 052 Phase 2a Trial Support Safety and Biological Activity Jan 06, 2011 4:59pm EST
XOMA and Servier Sign Development and Commercialization Agreement for XOMA 052 Jan 04, 2011 7:55am EST
XOMA to Host Conference Call and Webcast on January 4, 2011 to Provide Business Update Jan 03, 2011 6:41pm EST
XOMA Announces Presentation and Webcast at Lazard Capital Markets 7th Annual Healthcare Conference Nov 11, 2010 8:00am EST
Positive XOMA 052 Results in Inflammatory Eye Disease - Behcet's Uveitis - Presented at American College of Rheumatology Scientific Meeting Nov 10, 2010 8:00am EST
